Jardiance Administration via Feeding Tube
Jardiance (empagliflozin) tablets should NOT be routinely administered via feeding tube as this is an off-label use not supported by the FDA drug label, and crushing tablets carries risks of dosing inaccuracy, tube occlusion, and uncertain drug bioavailability.
Key Considerations
FDA Label Guidance
The Jardiance prescribing information 1 describes empagliflozin as "tablets for oral use" without any specific instructions or approval for administration via enteral feeding tubes. The label does not address crushing, dissolving, or alternative administration methods, which means feeding tube administration falls outside the approved Summary of Product Characteristics 2.
Critical Safety Concerns
Formulation Issues:
- Jardiance tablets contain a film coating with specific inactive ingredients (hypromellose, polyethylene glycol, talc, titanium dioxide, yellow ferric oxide) 1
- Crushing destroys the tablet integrity and may affect drug stability and absorption
- The drug's pharmacokinetic profile was established with intact tablets, not crushed formulations 1
Tube-Related Risks:
- Solid dosage forms have higher incidence of tube occlusions, particularly with nasogastric and silicone PEG tubes 2
- Drug-tube interactions can occur depending on tube material (polyurethane vs. silicone) 2
- Site of delivery matters—gastric vs. jejunal placement can significantly alter drug bioavailability 2
Clinical Decision Algorithm
If feeding tube administration is being considered:
Consult a pharmacist immediately 2—this is a Grade GPP strong consensus recommendation for any medication administered via feeding tube
Evaluate alternatives first:
- Can the patient's diabetes be managed with DPP-4 inhibitors (which have been studied in tube-fed patients)?
- Is insulin a safer option given the clinical uncertainty?
- Can SGLT2 inhibitor therapy be temporarily held if the patient's cardiovascular/renal benefits are not immediately critical?
If no alternative exists and tube administration is deemed necessary:
- Use only gastric tubes (not jejunal)—SGLT2 inhibitors require gastric absorption
- Crush tablet immediately before administration to minimize exposure 2
- Flush tube with 30 mL water before administration 2
- Administer crushed medication alone (never mix with other drugs) 2, 3
- Flush tube with 30 mL water after administration 2
- Stop enteral feeding 1 hour before and after to avoid potential drug-formula interactions 2
- Monitor glucose control closely—expect potentially reduced efficacy
- Document this as off-label use with informed consent
Important Caveats
Hypoglycemia Risk: The risk of hypoglycemia may be unpredictable when crushing Jardiance, especially in patients on concomitant insulin or sulfonylureas 4. The altered absorption profile could lead to either reduced efficacy or unexpected peaks in drug levels.
Renal Function Monitoring: Jardiance causes an initial eGFR decrease of ~5 mL/min within 1-2 weeks 5. This physiologic effect must be distinguished from tube-related malabsorption or drug accumulation. Check renal function 2 weeks after initiating crushed administration.
Volume Depletion: SGLT2 inhibitors increase urinary volume 1. In tube-fed patients who may already have altered fluid status, this risk is amplified. Ensure adequate fluid administration through the tube (beyond medication flushes) and monitor for orthostatic hypotension, particularly in elderly patients 1.
DKA Risk: Euglycemic DKA remains a concern 4, 6. Tube-fed patients often have reduced oral intake or are NPO for procedures—both are DKA risk factors. Discontinue Jardiance 3-4 days before any scheduled surgery 4, 7.
Practical Reality
The evidence gap is substantial: No published studies specifically evaluate empagliflozin stability or bioavailability when crushed and administered via feeding tube 8, 9. The 2026 landscape analysis found that only 18% of drug labels discuss pharmacokinetic effects of enteral tube administration 8.
Best practice in real-world medicine: If a patient absolutely requires both SGLT2 inhibitor therapy AND feeding tube nutrition, consider transitioning to insulin-based glucose management until oral intake resumes. The cardiovascular and renal benefits of empagliflozin 4, 7, 5 must be weighed against the risks of off-label crushing and uncertain bioavailability.